SynthesisPloS one2015
A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- [Use of antiparasitic drugs in the prevention of congenital toxoplasmosis: systematic review and meta-analysis].Medecine tropicale et sante internationale · 2025Pooled it
- A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies.European journal of medical research · 2021Pooled it
- Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis.Pathogens and global health · 2017Pooled it
- Quercetin ReducesInternational journal of molecular sciences · 2026Article
- Endogenous Amphiregulin promotes muscle repair and function through expansion of fibro-adipogenic progenitors during chronicFrontiers in microbiology · 2026Article
- Purification and Characterization of Immunoglobulin Y (IgY) Targeting Surface Antigen 1 (SAG1) ofAntibodies (Basel, Switzerland) · 2025Article
- Influenza virus-like particles presentingNanomedicine (London, England) · 2025Article
- Evaluation of anti-Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2025Article
- BthTX-II, an Asp49 PLAPharmaceuticals (Basel, Switzerland) · 2025Article
- Tartrolon E rapidly blocks Toxoplasma gondii capacity to invade host cells.International journal for parasitology. Drugs and drug resistance · 2025Article
- Phytochemical content of Cycas rumphii n-butanol fraction and antiprotozoal activity against Toxoplasma gondii in vivo.Scientific reports · 2025Article
- Testing for Antibodies to Four Parasites in Residual Blood Specimens from Trachoma Surveys in Kiribati, 2015-2019.The American journal of tropical medicine and hygiene · 2025Article
- High-Throughput Repurposing Screen Reveals Compounds with Activity againstACS infectious diseases · 2025Article
- Diseases Caused by and Behaviors Associated withPathogens (Basel, Switzerland) · 2024Review
- Immunomodulatory effect of propolisOpen veterinary journal · 2024Article
- High Throughput Repurposing Screen Reveals Compounds with Activity AgainstbioRxiv : the preprint server for biology · 2024Article
- Assessment of nebivolol efficacy in experimental models of toxoplasmosis: insights into parasite burden reduction and neuronal protection.Parasitology research · 2024Article
- Anti-Food science & nutrition · 2024Article
- Omega-3 and omega-6 polyunsaturated fatty acids and their potential therapeutic role in protozoan infections.Frontiers in immunology · 2024Review
- Lentinan has a beneficial effect on cognitive deficits induced by chronic Toxoplasma gondii infection in mice.Parasites & vectors · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No effective drug and definitive "gold standard" treatment for Toxoplasma gondii (T. gondii) infection has been available so far, though some medicines have been commonly used in the treatment of T. gondii infection, such as spiramycin, azithromycin, traditional Chinese medicine (TCM), pyrimethamine- sulfadiazine (P-S), trimethoprim-sulfamethoxazole (TMP-SMX), and pyrimethamine-clindamycin (P-C). A systematic review and meta-analysis were performed to compare the efficacies of these conventional medicines in the treatment. Cohort studies for the treatment of acute T. gondii infection were searched from PubMed, Google Scholar, ect. All the cases number for different group extracted from each included literature were input to meta-analysis 3.13 software to calculate the pooled negative conversion rate (NCR), cure rate (CR) or vertical transmission rate based on their sample size and weight. The pooled NCR with 95% confidence intervals (CI) was used to evaluate the overall rate of a diagnosis positive result conversion to a negative result after treatment, which of spiramycin, azithromycin and TCM were 83.4% (95%CI, 72.1%-90.8%), 82.5% (95%CI, 75.9%-87.6%), and 85.5% (95%CI, 71.3%-93.3%) respectively, with no statistical difference between them. The pooled CR with 95% CI was used to evaluate the overall rate of complete disappearance of clinical symptoms for toxoplasmic encephalitis after therapy, which of P-S, TMP-SMX, and P-C were 49.8% (95%CI, 38. 8% -60.8%), 59.9% (95%CI, 48.9%-70.0%), and 47.6% (95%CI, 24.8%-71.4%) respectively, with no statistical difference between them. Primary T. gondii infection in pregnancy was treated mainly with spiramycin alone or combined with other drugs, and the pooled rate of vertical transmission was about 9.9% (95%CI, 5.9%-16.2%) after therapy. Toxoplasmic encephalitis in AIDS patients was usually treated with sulfonamides combined with other drugs and the pooled CR was 49.4% (95%CI, 37.9%-60.9%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.